IP Library Granted Patent US 7,211,406
Granted Patent B2
US 7,211,406 · App. 10/451,892 · Granted May 1, 2007

Potassium channel

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,211,406
App. No.
10/451,892
Granted
May 1, 2007
Kind
B2
Abstract

A novel polypeptide which is useful in searching for a therapeutic agent for diabetes, a polynucleotide encoding the polypeptide, an expression vector comprising the polynucleotide, a cell transfected with the expression vector, an antibody binding to the polypeptide, and a method of screening a therapeutic agent for diabetes are disclosed. The polypeptide is a novel background potassium channel expressed in the pancreas.

Claims (15)

1. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 10 and exhibiting a background potassium channel activity.

2. An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 10.

3. An isolated polynucleotide encoding the polypeptide according to claims 1 or 2 .

4. An expression vector comprising the polynucleotide according to claim 3 .

5. A cell transfected with the expression vector according to claim 4 .

6. A method of screening agents to identify a therapeutic agent for the treatment of diabetes, comprising:

bringing a cell into contact with a test compound, wherein the cell is transfected with an expression vector comprising a polynucleotide encoding a polypeptide selected from:

(a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 10, and exhibiting a background potassium channel activity, and

(b) a polypeptide consisting of the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 10, and

analyzing whether the test compound suppresses the polypeptide, wherein a test compound that suppresses the polypeptide is identified as a therapeutic agent for the treatment of diabetes.

7. A method of screening agents to identify a therapeutic agent for the treatment of diabetes, comprising:

bringing a cell into contact with a test compound, wherein the cell is transfected with an expression vector comprising a polynucleotide encoding a polypeptide selected from:

(a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 and exhibiting a background potassium channel activity, and

(b) a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, and

analyzing whether the test compound suppresses the polypeptide, wherein a test compound that suppresses the polypeptide is identified as a therapeutic agent for the treatment of diabetes.

Assignments (2)
CHANGE OF NAME Recorded Nov 16, 2005
From: YAMANOUCHI PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 016784/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2003
From: YOKOI, HIROMICHI; INAMURA, KOHEI; SANO, YORIKATA; MIYAKE, AKIRA; MOCHIZUKI, SHINOBU
To: YAMANOUCHI PHARMACEUTICAL CO., LTD.
Reel/Frame 014552/0437 →